Consensus guideline on the use of inhaler devices in asthma

Mike Thomas, H. Chrystyn, J. Leyshon, David Brendan Price, J. Roberts, R. Russell

Research output: Other contribution


Asthma is a chronic respiratory disease characterised by variable
airflow limitation and airway hyper-responsiveness. It is highly
prevalent, affecting 5.2 million people in the UK.1 Effective inhaled
medications are available, which improve symptoms, pulmonary
function and quality of life and reduce exacerbations. However, for
many patients, symptoms remain poorly controlled.2,3 Incorrect use
of inhaler devices and/or non-compliance with inhaled medications are among several factors that compromise asthma management. 4,5 Furthermore, the result of inadequate asthma control has a significant impact on the overall costs of asthma. In the UK, the financial burden of this disease was estimated at almost £900 million,1 with lack of control responsible for up to 75% of costs.6
Original languageEnglish
TypeOnline supplement
PublisherMedendium Group Publishing Ltd
Number of pages8
Publication statusPublished - 1 Jun 2007

Publication series


Bibliographical note

This supplement has been supported by an educational grant from Teva UK Ltd. The views and opinions of contributors expressed in this publication are not necessarily those of Teva UK Ltd, Connectmedical or of Guidelines, its publisher, advisers and advertisers. No part of this publication may be reproduced in any form without the permission of the publisher.


Dive into the research topics of 'Consensus guideline on the use of inhaler devices in asthma'. Together they form a unique fingerprint.

Cite this